JNJ-2761 / J&J - LARVOL DELTA

A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - P1 | N=17 | Active, not recruiting | Sponsor: Janssen Research & Development, LLC | Recruiting ➔ Active, not recruiting | N=80 ➔ 17

Enrollment change • Enrollment closed • First-in-human • Hematological Malignancies • Multiple Myeloma • Oncology

A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - P1 | N=80 | Recruiting | Sponsor: Janssen Research & Development, LLC | Trial completion date: Nov 2028 ➔ Nov 2027

First-in-human • Trial completion date • Hematological Malignancies • Multiple Myeloma • Oncology

Discovery of JNJ-87562761, a novel anti-GPRC5D enhanced effector function (eEF) antibody with multiple mechanisms of action for the treatment of multiple myeloma (ASH 2025) - P1 | "JNJ-87562761 demonstrated potent in vitro activity with 3 distinct mechanisms as well aspotent in vivo activity in 2 MM xenograft models. The safety and preliminary efficacy of JNJ-87562761 iscurrently being evaluated in a Phase 1 study of participants with relapsed/refractory MM (NCT06604715)."

IO biomarker • Hematological Malignancies • Multiple Myeloma • GPRC5D • IL15

A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - P1 | N=80 | Recruiting | Sponsor: Janssen Research & Development, LLC | Not yet recruiting ➔ Recruiting | Trial completion date: Nov 2027 ➔ Nov 2028

Enrollment open • Trial completion date • Hematological Malignancies • Multiple Myeloma • Oncology

A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - P1 | N=80 | Not yet recruiting | Sponsor: Janssen Research & Development, LLC

New P1 trial • Hematological Malignancies • Multiple Myeloma • Oncology